Detalhe da pesquisa
1.
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Bioorg Med Chem Lett
; 29(1): 83-88, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30463802
2.
Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.
Bioorg Med Chem Lett
; 24(7): 1790-4, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24618302
3.
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Bioorg Med Chem Lett
; 22(8): 2932-7, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22421020
4.
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.
ACS Med Chem Lett
; 13(8): 1321-1328, 2022 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35978696
5.
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
Bioorg Med Chem Lett
; 21(7): 2034-9, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21334892
6.
The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
Bioorg Med Chem Lett
; 21(1): 497-501, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21075628
7.
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
Bioorg Med Chem Lett
; 21(15): 4622-8, 2011 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21700453
8.
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Bioorg Med Chem Lett
; 21(6): 1748-53, 2011 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21316962
9.
Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor.
Bioorg Med Chem Lett
; 21(1): 506-9, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21075630
10.
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
Bioorg Med Chem Lett
; 21(10): 3163-7, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21458261
11.
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
Bioorg Med Chem Lett
; 21(8): 2541-6, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411321
12.
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
J Med Chem
; 64(8): 5018-5036, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783225
13.
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
Bioorg Med Chem Lett
; 20(24): 7327-30, 2010 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21074434
14.
The discovery and SAR of indoline-3-carboxamides--a new series of 5-HT6 antagonists.
Bioorg Med Chem Lett
; 20(12): 3713-6, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20471831
15.
Rapid access towards follow-up NOP receptor agonists using a knowledge based approach.
Bioorg Med Chem Lett
; 19(22): 6441-6, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19818611
16.
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
J Med Chem
; 62(6): 2988-3008, 2019 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30840447
17.
Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties.
Bioorg Med Chem
; 16(6): 2829-51, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18249547
18.
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
ACS Med Chem Lett
; 7(1): 34-9, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26819662
19.
De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
ACS Chem Biol
; 8(5): 1044-52, 2013 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23534475
20.
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
J Med Chem
; 56(24): 9934-54, 2013 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24261862